A retrospective cohort study that used different methods evaluated TNF inhibitor exposure in a large cohort of patients with inflammatory bowel disease; it did not find a difference in the risk of developing an inflammatory demyelinating disease in patients exposed to TNF inhibitors.45 Because of the rarity of these inflammatory CNS events, we were limited by power to analyze each autoimmune disease and its association with TNF inhibitor exposure. Here, TNF is linked to inflammatory bowel disease.